New hope for VHL patients: belzutifan trial targets rare tumor disorder
NCT ID NCT07167329
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests the drug belzutifan in 100 people with von Hippel-Lindau (VHL) syndrome, a genetic condition that causes tumors in various organs. Researchers will track how well the drug shrinks tumors and how long it takes for the disease to progress, while also monitoring side effects like anemia. The goal is to see if belzutifan can effectively control VHL-related tumors in a real-world setting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- belzutifan
- What this could lead to
- If successful, this could show that belzutifan effectively shrinks or controls VHL-related tumors, offering a targeted treatment option for this rare genetic condition.
- What could go wrong
- This is a phase 2 study with only 100 participants, so results may not apply to all VHL patients. Side effects like anemia are possible, and the drug may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOLYMPHATIC SAC TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AC Camargo Cancer Center
RECRUITINGSão Paulo, São Paulo, 01509900, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists track hidden brain tumors in children with rare genetic condition
- Could a daily pill tame rare cancers in teens? new trial investigates
- Could a cancer drug quiet overactive adrenal hormones? a new study investigates.
- Can a Stress-Busting program help VHL patients cope better?
- New imaging agent could improve detection of rare cancers
- New PET scan agent aims to sharply detect multiple cancers